Literature DB >> 3059081

Malignant mesothelioma of the pleura.

R J Pisani1, T V Colby, D E Williams.   

Abstract

Malignant mesothelioma of the pleura most commonly occurs in persons with a heavy occupational exposure to asbestos. Some patients, however, have no such history of exposure. Clinical features include initial complaints of nonpleuritic chest pain and dyspnea. The most frequent roentgenographic finding is a unilateral pleural effusion. Thrombocytosis and elevated erythrocyte sedimentation rates are common. Pleural effusions are typically exudates, are often hemorrhagic, and are usually insufficient for diagnosing mesothelioma based on cytology alone. Even pleural biopsy may not produce enough tissue to enable the pathologist to make a firm diagnosis. Thoracotomy and open biopsy will confirm the diagnosis in most cases. Pathologic distinction from metastatic adenocarcinoma may be difficult even after the use of special stains and electron microscopy. Clinical deterioration is primarily attributable to local spread of tumor. Several factors seem to predict prolonged survival: (1) epithelial histologic subtype, (2) performance score, (3) age of the patient at the time of diagnosis, and (4) absence of chest pain. Surgical treatment, chemotherapy, and irradiation, alone or in combination, have been used for malignant mesothelioma. Except for the palliative effect of irradiation, most treatment protocols have not altered the dismal median survival of approximately 11 months seen in untreated patients with malignant mesothelioma.

Entities:  

Mesh:

Year:  1988        PMID: 3059081     DOI: 10.1016/s0025-6196(12)65411-1

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  12 in total

1.  Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients.

Authors:  Emin Tamer Elkiran; Mehmet Ali Kaplan; Alper Sevinc; Sercan Aksoy; Umut Demirci; Mesut Seker; Hakan Harputluoglu; Nuriye Yildirim Ozdemir; Feridun Isik; Arife Ulas; Mevlude Inanc; Ulku Yalcintas Arslan; Gamze Gokoz Dogu; Abdurrahman Isikdogan; Suleyman Buyukberber
Journal:  Med Oncol       Date:  2012-06-22       Impact factor: 3.064

Review 2.  Biopsies in patients with intrathoracic disease.

Authors:  G A Lillington; W SooHoo
Journal:  Clin Rev Allergy       Date:  1990 Summer-Fall

3.  Value of serum and effusion fluid CEA levels for distinguishing between diffuse malignant mesothelioma and carcinomatous pleural metastases.

Authors:  J Mezger; A Calavrezos; P Drings; U Gatzemeier; E Kaukel; N Konietzko; G Koschel; R Lamerz; J von Pawel; W Römer
Journal:  Lung       Date:  1994       Impact factor: 2.584

4.  Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma.

Authors:  K M Amin; L A Litzky; W R Smythe; A M Mooney; J M Morris; D J Mews; H I Pass; C Kari; U Rodeck; F J Rauscher
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

5.  Treatment of a patient with malignant mesothelioma with interferon-alpha 2 based on in vitro sensitivity tests.

Authors:  V Sexl; L Wagner; M Wiesholzer; E Presterl; W Base
Journal:  Clin Investig       Date:  1994-03

Review 6.  Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.

Authors:  Andrew R Haas; Daniel H Sterman
Journal:  Clin Chest Med       Date:  2013-01-17       Impact factor: 2.878

Review 7.  Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment.

Authors:  Sandip Basu; Babak Saboury; Drew A Torigian; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

Review 8.  Diffuse neoplasms of the pleural serosa.

Authors:  L Cardinale; F Ardissone; F Asteggiano; E M Laugelli; D Penna; C Fava
Journal:  Radiol Med       Date:  2012-09-17       Impact factor: 3.469

9.  Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.

Authors:  Ayse Mavi; Sandip Basu; Tevfik F Cermik; Muammer Urhan; Mehdi Bathaii; Dhurairaj Thiruvenkatasamy; Mohamed Houseni; Simin Dadparvar; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2009-05-27       Impact factor: 3.488

Review 10.  Radiotherapy for malignant pleural mesothelioma.

Authors:  E Chapman; E G Berenstein; M Diéguez; Z Ortiz
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.